NCLAT ends insolvency proceedings for Shilpa Medicare subsidiary
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On 4 November 2026, the National Company Law Appellate Tribunal set aside the 9 September NCLT order that admitted FTF Pharma Private Limited, Shilpa Medicare's wholly owned subsidiary, into insolvency resolution. The appeal concerned three disputed invoices totaling Rs 2.18 crore. The insolvency process is closed, the moratorium has ended, and the subsidiary's board and management have been restored. Shilpa Medicare reports no financial or operational impact.
Positive for Shilpa Medicare: FTF Pharma avoids an insolvency process and regains normal control. The company reports no financial or operational impact.